| A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function (NCT02372084) | Novartis Pharmaceuticals | 2015-04-21 |
| PCA062 in pCAD-positive Tumors. (NCT02375958) | Novartis Pharmaceuticals | 2015-04-15 |
| Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients (NCT02421172) | Novartis Pharmaceuticals | 2015-04-13 |
| A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) (NCT02394561) | Novartis Pharmaceuticals | 2015-04-10 |
| Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT02299505) | Novartis Pharmaceuticals | 2015-04-09 |
| Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (NCT02257632) | Novartis Pharmaceuticals | 2015-04-08 |
| Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (NCT02435849) | Novartis Pharmaceuticals | 2015-04-08 |
| An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA) (NCT02268552) | Novartis Pharmaceuticals | 2015-04-02 |
| A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain (NCT02476422) | Novartis Pharmaceuticals | 2015-04-01 |
| A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (NCT02336451) | Novartis Pharmaceuticals | 2015-04-01 |
| Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (NCT02474082) | Novartis Pharmaceuticals | 2015-04-01 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues (NCT02354508) | Novartis Pharmaceuticals | 2015-03-31 |
| Fingolimod Effect on Cytokine and Chemokine Levels (NCT02373098) | Novartis Pharmaceuticals | 2015-03-31 |
| Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011 (NCT02388620) | Novartis Pharmaceuticals | 2015-03-25 |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma (NCT02343172) | Novartis Pharmaceuticals | 2015-03-13 |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations (NCT02381886) | Novartis Pharmaceuticals | 2015-03-06 |
| CINC424A2X01B Rollover Protocol (NCT02386800) | Novartis Pharmaceuticals | 2015-03-05 |
| Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients (NCT02404389) | Novartis Pharmaceuticals | 2015-03-05 |
| Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma (NCT02127697) | Novartis Pharmaceuticals | 2015-03-01 |
| Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients (NCT02143622) | Novartis Pharmaceuticals | 2015-03-01 |
| A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression (NCT02300987) | Novartis Pharmaceuticals | 2015-02-26 |
| Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (NCT02366468) | Novartis Pharmaceuticals | 2015-02-23 |
| Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (NCT02253277) | Novartis Pharmaceuticals | 2015-02-18 |
| Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer (NCT02323126) | Novartis Pharmaceuticals | 2015-02-09 |
| Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (NCT02474069) | Novartis Pharmaceuticals | 2015-02-08 |
| CCFZ533X2201 - PoC Study in de Novo Renal Transplantation (NCT02217410) | Novartis Pharmaceuticals | 2015-02-05 |
| A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (NCT02333370) | Novartis Pharmaceuticals | 2015-02-04 |
| First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers (NCT02334449) | Novartis Pharmaceuticals | 2015-02-01 |
| Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (NCT02248922) | Novartis Pharmaceuticals | 2015-01-27 |
| A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NCT02276027) | Novartis Pharmaceuticals | 2015-01-20 |
| Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations (NCT02124772) | Novartis Pharmaceuticals | 2015-01-15 |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. (NCT02335944) | Novartis Pharmaceuticals | 2015-01-13 |
| Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (NCT02362789) | Novartis Pharmaceuticals | 2015-01-04 |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression (NCT02325739) | Novartis Pharmaceuticals | 2014-12-29 |
| A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan) (NCT02626221) | Novartis Pharmaceuticals | 2014-12-24 |
| Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus (NCT02338609) | Novartis Pharmaceuticals | 2014-12-17 |
| Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer (NCT02294786) | Novartis Pharmaceuticals | 2014-12-17 |
| Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma (NCT02290431) | Novartis Pharmaceuticals | 2014-12-16 |
| Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME (NCT02262260) | Novartis Pharmaceuticals | 2014-12-12 |
| Dose Range Finding Study of Bimagrumab in Sarcopenia (NCT02333331) | Novartis Pharmaceuticals | 2014-12-09 |
| Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia (NCT02221505) | Novartis Pharmaceuticals | 2014-12-01 |
| Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (NCT02069886) | Novartis Pharmaceuticals | 2014-12-01 |
| Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients (NCT02329223) | Novartis Pharmaceuticals | 2014-12-01 |
| A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD) (NCT02233543) | Novartis Pharmaceuticals | 2014-11-30 |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. (NCT02292446) | Novartis Pharmaceuticals | 2014-11-21 |
| Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (NCT02278120) | Novartis Pharmaceuticals | 2014-11-20 |
| ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab (NCT02296424) | Novartis Pharmaceuticals | 2014-11-17 |
| PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod (NCT02335892) | Novartis Pharmaceuticals | 2014-11-11 |
| A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients (NCT02259088) | Novartis Pharmaceuticals | 2014-11-05 |
| A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies (NCT02334748) | Novartis Pharmaceuticals | 2014-11-03 |
| Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection (NCT02058108) | Novartis Pharmaceuticals | 2014-10-31 |
| Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer (NCT02213042) | Novartis Pharmaceuticals | 2014-10-24 |
| Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome (NCT02291029) | Novartis Pharmaceuticals | 2014-10-22 |
| Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction (NCT02226120) | Novartis Pharmaceuticals | 2014-10-16 |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors (NCT01956669) | Novartis Pharmaceuticals | 2014-10-08 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant (NCT01930162) | Novartis Pharmaceuticals | 2014-10-07 |
| Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease (NCT02180217) | Novartis Pharmaceuticals | 2014-10-06 |
| Study of Afuresertib Combined With Paclitaxel in Gastric Cancer (NCT02240212) | Novartis Pharmaceuticals | 2014-10-01 |
| Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks (NCT02232061) | Novartis Pharmaceuticals | 2014-09-29 |
| Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (NCT02267135) | Novartis Pharmaceuticals | 2014-09-29 |
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (NCT02186821) | Novartis Pharmaceuticals | 2014-09-17 |
| Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery (NCT02152761) | Novartis Pharmaceuticals | 2014-09-16 |
| Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model (NCT04072302) | Novartis Pharmaceuticals | 2014-09-15 |
| Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. (NCT02159040) | Novartis Pharmaceuticals | 2014-09-11 |
| Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure (NCT02151383) | Novartis Pharmaceuticals | 2014-09-05 |
| AWARE - Chronic Urticaria (NCT02435238) | Novartis Pharmaceuticals | 2014-09-03 |
| Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies (NCT02160951) | Novartis Pharmaceuticals | 2014-09-01 |
| A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) (NCT02091752) | Novartis Pharmaceuticals | 2014-09-01 |
| Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (NCT02161575) | Novartis Pharmaceuticals | 2014-08-28 |
| Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) (NCT02202616) | Novartis Pharmaceuticals | 2014-08-27 |
| LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) (NCT02187783) | Novartis Pharmaceuticals | 2014-08-25 |
| Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (NCT02228096) | Novartis Pharmaceuticals | 2014-08-14 |
| Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients (NCT02177682) | Novartis Pharmaceuticals | 2014-08-13 |
| Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies (NCT02189174) | Novartis Pharmaceuticals | 2014-08-07 |
| 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (NCT01948791) | Novartis Pharmaceuticals | 2014-08-01 |
| Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients (NCT02178540) | Novartis Pharmaceuticals | 2014-08-01 |
| Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (NCT02150213) | Novartis Pharmaceuticals | 2014-08-01 |
| OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients (NCT02161562) | Novartis Pharmaceuticals | 2014-08-01 |
| Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (NCT02205398) | Novartis Pharmaceuticals | 2014-07-28 |
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations (NCT02160041) | Novartis Pharmaceuticals | 2014-07-24 |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma (NCT02144038) | Novartis Pharmaceuticals | 2014-07-23 |
| A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia (NCT02148133) | Novartis Pharmaceuticals | 2014-07-23 |
| Global Non-interventional Heart Failure Disease Registry (NCT02595814) | Novartis Pharmaceuticals | 2014-07-23 |
| Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (NCT01920711) | Novartis Pharmaceuticals | 2014-07-18 |
| A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (NCT02272777) | Novartis Pharmaceuticals | 2014-07-17 |
| Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) (NCT02125877) | Novartis Pharmaceuticals | 2014-07-08 |
| Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. (NCT02108951) | Novartis Pharmaceuticals | 2014-07-07 |
| Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt (NCT02143635) | Novartis Pharmaceuticals | 2014-07-07 |
| A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374 (NCT02245828) | Novartis Pharmaceuticals | 2014-07-01 |
| Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (NCT02154776) | Novartis Pharmaceuticals | 2014-06-27 |
| Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (NCT02059291) | Novartis Pharmaceuticals | 2014-06-27 |
| Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients (NCT01818726) | Novartis Pharmaceuticals | 2014-06-23 |
| Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss (NCT02132130) | Novartis Pharmaceuticals | 2014-06-23 |
| High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV) (NCT03070717) | Novartis Pharmaceuticals | 2014-06-12 |
| A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (NCT02034006) | Novartis Pharmaceuticals | 2014-06-10 |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) (NCT02158936) | Novartis Pharmaceuticals | 2014-06-10 |
| A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies (NCT02108964) | Novartis Pharmaceuticals | 2014-06-06 |
| Long-term Follow-up of Fingolimod Phase II Study Patients (NCT02307838) | Novartis Pharmaceuticals | 2014-06-01 |
| Safety and Efficacy of Fingolimod in MS Patients in China (NCT01941004) | Novartis Pharmaceuticals | 2014-06-01 |
| Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD (NCT02055352) | Novartis Pharmaceuticals | 2014-05-30 |